Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
dc.contributor.author | Dal, Mehmet Sinan | |
dc.contributor.author | Ulu, Bahar Uncu | |
dc.contributor.author | Uzay, Ant | |
dc.contributor.author | Akay, Olga Meltem | |
dc.contributor.author | Besisik, Sevgi | |
dc.contributor.author | Yenerel, Mustafa Nuri | |
dc.contributor.author | Celik, Serhat | |
dc.contributor.author | Kaynar, Leylagul | |
dc.contributor.author | Yucel, Orhan Kemal | |
dc.contributor.author | Deveci, Burak | |
dc.contributor.author | Sonmez, Mehmet | |
dc.contributor.author | Mehtap, Ozgur | |
dc.contributor.author | Bekoz, Huseyin Saffet | |
dc.contributor.author | Sunu, Cenk | |
dc.contributor.author | Salim, Ozan | |
dc.contributor.author | Ulas, Turgay | |
dc.contributor.author | Karti, Sami | |
dc.contributor.author | Altuntas, Fevzi | |
dc.contributor.author | Ferhanoglu, Burhan | |
dc.contributor.author | Tuglular, Tulin Firat | |
dc.date.accessioned | 2023-02-21T12:41:56Z | |
dc.date.available | 2023-02-21T12:41:56Z | |
dc.date.issued | 2023-01-01 | |
dc.description.abstract | Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9\%, including 32.4\% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile. | |
dc.description.issue | 1 | |
dc.description.issue | JAN | |
dc.description.pages | 133-140 | |
dc.description.volume | 102 | |
dc.identifier.doi | 10.1007/s00277-022-05052-x | |
dc.identifier.uri | https://hdl.handle.net/11443/2767 | |
dc.identifier.uri | http://dx.doi.org/10.1007/s00277-022-05052-x | |
dc.identifier.wos | WOS:000885401400002 | |
dc.publisher | SPRINGER | |
dc.relation.ispartof | ANNALS OF HEMATOLOGY | |
dc.subject | Diffuse large B-cell lymphoma | |
dc.subject | Polatuzumab vedotin | |
dc.subject | Refractory | |
dc.subject | Relapsed | |
dc.subject | Rituximab | |
dc.subject | Bendamustine | |
dc.title | Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey | |
dc.type | Article |